Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy

This publication has 39 references indexed in Scilit:

• Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients
  Journal of Cancer Research and Clinical Oncology, 2012
• Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
  Clinical Cancer Research, 2010
• Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients
  Breast Cancer Research and Treatment, 2010
• Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
  Breast Cancer Research, 2010
• Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
  British Journal of Cancer, 2010
• In Response to “Drug Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort”
  Journal of Clinical Oncology, 2007
• F-SNP: computationally predicted functional SNPs for disease association studies
  Nucleic Acids Research, 2007
• Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer
  Journal of Clinical Oncology, 2005
• CYP3A5 phenotype‐genotype correlations in a British population
  British Journal of Clinical Pharmacology, 2003
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI: Journal of the National Cancer Institute, 2000